Capital L P Double Black Di... Net Worth

The estimated Net Worth of Capital L P Double Black Di... is at least $11.1 Milhão dollars as of 15 August 2023. Capital Di owns over 216,000 units of Tff Pharmaceuticals Inc stock worth over $10,988,880 and over the last few years Capital sold TFFP stock worth over $95,040.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Di TFFP stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Tff Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Capital sold 216,000 units of TFFP stock worth $95,040 on 15 August 2023.

The largest trade Capital's ever made was selling 216,000 units of Tff Pharmaceuticals Inc stock on 15 August 2023 worth over $95,040. On average, Capital trades about 216,000 units every 0 days since 2023. As of 15 August 2023 Capital still owns at least 5,064,000 units of Tff Pharmaceuticals Inc stock.

You can see the complete history of Capital Di stock trades at the bottom of the page.

Insiders trading at Tff Pharmaceuticals Inc

Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher, eHarlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.

What does Tff Pharmaceuticals Inc do?

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.

Complete history of Capital Di stock trades at Tff Pharmaceuticals Inc

Tff Pharmaceuticals Inc executives and stock owners

Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Glenn R. Mattes,
  Pres, CEO & Director
• Kirk Allen Coleman,
  CFO, Treasurer & Sec.
• Christopher Cano,
  COO & VP of Bus. Devel.
• Paul F. Manley,
  Head of Regulatory Affairs
• Dr. Anthony J. Hickey Ph.D.,
  Chief Scientific Officer
• Dr. Dale Christensen,
  Director of Clinical Devel.
• Dr. James Brian Windsor Ph.D.,
  Chief Science Officer & Director
• Dr. James Brian Windsor,
  Chief Science Officer & Director
• Malcolm Fairbairn,
  Director
• Zamaneh Mikhak,
  Chief Medical Officer
• Robert S Mills,
  Director
• Glenn R. Mattes,
  President and CEO
• James Brian Windsor,
  Chief Science Officer
• Aaron G.L. Fletcher,
  Director
• Randy H Thurman,
  Director
• Brandi Roberts,
  Director
• Stephen Rocamboli,
  Director
• Therapeutics, Inc. Lung,
  10% owner
• Michael A Patane,
  Director
• Catherine Chai Zon Lee,
  Director
• Christopher Cano,
  Chief Operating Officer
• Harlan F Weisman,
  President and CEO
• Kirk Allen Coleman,
  Chief Financial Officer
• Capital L P Double Black Di...,
  
• Thomas Braxton King,
  Director